NCT02253316 2025-11-10Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple MyelomaWashington University School of MedicinePhase 2 Active not recruiting236 enrolled 13 charts